Welcome to our dedicated page for Pacira BioSciences SEC filings (Ticker: PCRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Pacira BioSciences filings document a life sciences company's financial results, governance actions, credit arrangements and manufacturing-related corporate events. Recent Form 8-K reports furnish quarterly and annual results for the commercial portfolio, including EXPAREL, ZILRETTA and iovera, and disclose the company's common stock listing on the Nasdaq Global Select Market under PCRX.
The filing record also covers board composition and committee appointments, non-employee director compensation, senior secured revolving credit facility terms, and exit or disposal activities associated with EXPAREL manufacturing efficiencies and large-scale production suites. These disclosures frame Pacira's capital structure, liquidity arrangements, operating costs, governance and product-manufacturing infrastructure.
Pacira BioSciences, Inc. Chief Medical Officer Jonathan Slonin reported a routine tax-related share disposition. On the reported date, 4,728 shares of common stock were withheld by the company to cover tax obligations when a restricted stock unit award vested. After this withholding, Slonin directly holds 218,912.175 shares of Pacira BioSciences common stock. This event reflects tax withholding rather than an open-market sale or purchase.
Pacira BioSciences Chief Administrative Officer Kristen Williams sold 10,259 shares of common stock in an open-market trade at $22.27 per share on June 4, 2026. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan adopted on September 10, 2025.
One day earlier, on June 3, 2026, 8,528 shares were withheld at $22.32 per share to cover tax obligations upon vesting of a restricted stock unit award, which is a non-market, compensation-related event. After these transactions, Williams directly holds 167,062 Pacira shares.
DOMA Perpetual has filed a definitive proxy statement to nominate three directors and is soliciting votes via a WHITE proxy card for Pacira BioSciences’ 2026 annual meeting.
DOMA states it beneficially owns approximately 7.5% of Pacira common stock and cites specific holdings aggregating 2,777,794 shares across affiliated entities. DOMA’s release includes a May 20, 2026 joint letter from two independent nominees, Christopher Dennis and Oliver "Ben" Curtis III, who argue their clinical, compliance, and legal backgrounds address the company’s strategic and oversight gaps and urge shareholders to vote for all three DOMA nominees in advance of the June 9, 2026 meeting.
DOMA Perpetual filed a preliminary proxy statement seeking to elect three director nominees to Pacira BioSciences' board and to replace management ahead of the June 9, 2026 annual meeting. The filing says DOMA and affiliates beneficially own up to 2,777,794 shares and argues the board mismanaged EXPAREL litigation and capital allocation.
DOMA contends EXPAREL represents ~80% of Pacira revenue, cites a prior court loss and settlement that it says ceded roughly 38% of future EXPAREL volumes, and proposes removal of the CEO, formation of a sales-focused subcommittee, and shareholder approval of any sale.
Pacira BioSciences reported that Vanguard Portfolio Management beneficially owned 2,585,964 shares of common stock, representing 6.38% of the class as of 03/31/2026. The filing discloses sole voting power of 84,678 shares and sole dispositive power over 2,585,964 shares. The Schedule 13G states these holdings reflect securities managed by Vanguard Portfolio Management LLC and affiliated investment divisions and was signed on 05/01/2026.
Vanguard Capital Management reported beneficial ownership of 2,088,291 shares of Pacira BioSciences Inc common stock, representing 5.15% of the class as of 03/31/2026. The filing states Vanguard has sole dispositive power over 2,088,291 shares and sole voting power over 304,242 shares.
The filing attributes ownership to Vanguard Capital Management and affiliated Vanguard entities and is signed by a representative on 05/01/2026.